Winton Group’s Procept Biorobotics PRCT Stock Holding History

Winton Group’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,569	Closed	-$207K	–	770
2024 Q4	$207K	Buy	+2,569	New	+$219K	0.01%	563

Other funds holding PRCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Winton Group's PRCT Position: Q1 2025 in Review

Winton Group sold out of Procept Biorobotics (PRCT) in Q1 2025, closing a stake of 2,569 shares — an estimated $207K sold.

Winton Group first reported a position in PRCT in Q4 2024 and held it in 1 quarter. The position peaked at $207K in Q4 2024. 279 funds tracked by Wall St. Rank hold PRCT as of Q1 2025.

Winton Group reported no remaining Procept Biorobotics position as of Q1 2025 after selling out during the quarter.
Winton Group sold 2,569 Procept Biorobotics shares in Q1 2025, an estimated $207K.
Winton Group first reported a position in Procept Biorobotics in Q4 2024 and held it in 1 quarter.
Winton Group's Procept Biorobotics position peaked at $207K in Q4 2024.
279 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2025.

Based on Winton Group's 13F filing for Q1 2025, filed 15 May 2025.